LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases
MedComm · 2026-03 · 7 (3)
DOI: 10.1002/mco2.70601 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 24.02.2026. Verfasst von Zhuo Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery & the Center for Basic Medical Research TEDA International Cardiovascular Hospital, Tianjin University Tianjin C…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The LKB1–AMPK signaling pathway is a master regulator of cellular energy homeostasis and a central hub in stress adaptation. As a conserved metabolic sensor, this pathway coordinates glucose, lipid, and protein metabolism, thereby sustaining physiological function across diverse tissues. Beyond its canonical role in energy balance, growing evidence highlights its dysregulation in multiple pathological conditions. Despite extensive mechanistic studies, the disease‐specific regulation and translational potential of the LKB1–AMPK pathway remain incompletely understood. This review systematically studies the molecular basis and regulatory mechanisms of LKB1–AMPK signaling in cardiovascular diseases—including atrial fibrillation, ventricular fibrillation, myocardial infarction, cardiac hypertrophy, heart failure, and atherosclerosis—where impaired pathway activity underlies energy deficits, fibrosis, oxidative stress, and arrhythmogenesis. We further explore its involvement in metabolic disorders such as diabetes and diabetic nephropathy, in neurodegenerative diseases like Alzheimer's and Parkinson's disease, and in oncology, where LKB1 mutations drive tumorigenesis and alter therapeutic responses. Emerging strategies, including metformin, novel AMPK activators, and LKB1‐based gene therapies, are highlighted as promising yet challenged by tissue specificity, off‐target effects, and genetic variation. By integrating insights from cardiovascular, metabolic, neurological, and oncological research, this review underscores the pathway's potential as both a biomarker source and therapeutic target, providing a foundation for precision medicine in complex diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery & the Center for Basic Medical Research TEDA International Cardiovascular Hospital, Tianjin University Tianjin China.
- Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine Tianjin China.
- The Institute of Cardiovascular Diseases, Tianjin University Tianjin China.
- TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences Tianjin China.
Zitieren
APA
Chen, Z., Yang, Q., & He, G. W. (2026). LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases. MedComm, 7(3). https://doi.org/10.1002/mco2.70601
Vancouver
Chen Z, Yang Q, He GW. LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases. MedComm. 2026;7(3). doi:10.1002/mco2.70601
BibTeX
@article{Chen2026,
author = {Chen, Zhuo and Yang, Qin and He, Guo-Wei},
title = {LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases},
journal = {MedComm},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/mco2.70601}
}
EUVIMED